T cells are normally a major component of tumor-infiltrating immune cells. 3 Recently, a subset of regulatory T cells (Tregs) with potent immunosuppressive properties has been detected in human GC, and increased such Tregs was also associated with poor prognosis of GC patients. 4 Although most data on circulating 5 or tumor-infiltrating 6 Tregs belonged to CD4 + CD25 + Foxp3 + T cells, little is known about the phenotype, regulation, function, and clinical relevance of Treg subsets in human gastric tumors.
Generally, Tregs, like other T cells, can be divided into CD45RA + naïve and CD45RA − memory subtypes. 7 The memory population can be further characterized into: CD45RA − (terminally differentiated).
8
CD45RA is located on naïve T cells and when they are activated or transformed into memory cells, CD45RA is lost. CCR7, a seven transmembrane G protein-coupled chemokine receptor, is essential for the migration of T cells and dendritic cells (DCs) to the surrounding lymphoid tissue or the site of immune response by binding to its ligands, 9 mainly expressed on the cell surface of T cells 10 and DCs, 11 as well as some tumor cells. However, the regulatory mechanisms of such Treg subsets, especially in human GC, need to be further elucidated.
In this study, we investigated the number, distribution and phenotype of Tregs and their subsets in GC. We show that a novel Treg subset with CD45RA −
CCR7
− effector/memory phenotype constitutes most tumor-infiltrating Tregs and that this Treg subset is highly enriched in GC with disease progression and negatively correlated with patient survival following surgery. Moreover, we demonstrated that gastric tumor-derived TNF-α efficiently induced CD45RA −
− Treg subset and inhibited HLA-DR expression on these cells by inducing signal transducer and activator of transcription 3 (STAT3) phosphorylation. In turn, this CD45RA −
− Treg subset suppresses CD8 + T-cell anti-tumor function via IL-10 secretion and cell-cell contact mechanisms, and, in doing so, contribute to the immunosuppression and GC progression.
Results
Tregs are enriched in GC with a classical profile. To evaluate the potential role of Tregs and its subsets in human 1 
GC, we first gated CD4
+ CD25 + Foxp3 + T lymphocytes as Tregs and analyzed the Treg percentage within the total CD4 + T-cell populations from peripheral blood, non-tumor, peritumoral, and tumor tissues of GC patients. Peripheral blood from healthy donors was included as a control. Notably, patients with GC showed a higher frequency of Tregs in peripheral blood than healthy donors (Figures 1a and b) . Within the patient cohort, tumors contained a significantly higher proportion of Tregs than non-tumor, or peritumoral tissues (Figures 1a and b) , suggesting a potential role for Tregs in the GC microenvironment. We also performed immuno-phenotyping of intratumoral Tregs to better understand their likely status. Gating on intratumoral Tregs, we found that Tregs expressed glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), CTLA-4, and CCR4 (Figure 1b ), indicating that most intratumoral Tregs were classical immunosuppressive lymphocytes. On the basis of our observation, we conclude that tumor-infiltrating Tregs accumulated in the GC microenvironment and may perform immunosuppressive functions in GC patients.
CD45RA

−
CCR7
− effector/memory phenotype Treg subset constitutes most tumor-infiltrating Tregs and accumulated in GC. To study phenotypic features of Tregs at tumor site, we gated on intratumoral Tregs, and found that most Foxp3 + Tregs belonged to the CD45RA − memory T-cell phenotype ( Figure 1c) . Next, we also found that intratumoral Tregs expressed little homing molecule CCR7 (Figure 1c ), suggesting that they may be permanent residents, and have high potential to exert effector function in GC. Finally, we examined Treg subsets according to the expression of both CD45RA and CCR7, and found that most intratumoral Tregs displayed a CD45RA
−
CCR7
− effector/memory phenotype (Figures 1d and e) , whereas non-tumor tissue-derived Tregs displayed largely more CD45RA − CCR7 + central memory phenotype (Figures 1d and e) . In addition, there were no differences of CD45RA + CCR7 − and CD45RA + CCR7 + Treg subset percentages between tumors and non-tumor tissues (Figures 1d and e) , which constituted no more than 10% total Tregs. Within the patient cohort, tumors contained a significantly higher CD45RA 
− Treg subset in GC is induced by tumorderived TNF-α. Given the superior ability of Tregs to exhibit CD45RA −
− effector/memory phenotype in GC, we hypothesized that tumor microenvironment itself might play important roles in this process. To test this hypothesis, peripheral derived-Tregs were purified and cultured with tumor tissue culture supernatants (TTCS) or non-tumor tissue culture supernatants (NTCS) for 24 h. Interestingly, more TTCSconditioned Tregs showed CD45RA −
− phenotype than NTCS-conditioned Tregs (Figure 2a) (Figure 2 ), and CCR7 expression on immune cells is regulated by pro-inflammatory cytokine TNF-α, 12 we hypothesized that TNF-α might regulate CCR7 expression on Treg subsets in GC. Firstly, we found a significantly increased TNF-α production (Figure 2b ) as well as a positive correlation between CD45RA −
− Treg subset and TNF-α within gastric tumors ( Figure 2b) ; next, to evaluate the potential role of TNF-α in CD45RA −
− Treg subset induction, we co-cultured TNF-α and purified-Tregs, and found that TNF-α significantly increased the frequency of CD45RA −
− Treg subset whereas inhibited CD45RA − CCR7 + Treg subset (Figure 2c ). To further evaluate tumorderived TNF-α in this induction, we added neutralizing antibody against TNF-α into our TTCS and purified-Treg co-culture system. Interestingly, antibody blockade of TNF-α efficiently decreased the frequency of CD45RA 
− Treg subsets after Tregs exposed to TNF-α (c), or after Tregs exposed to TTCS with anti-TNF-α antibody (d), or after Tregs exposed to NTCS with TNF-α (e) for 24 h. Each dot in panel b represents one patient. *, Po0.05; **, Po0.01, and n.s., P40.05 for groups connected by horizontal lines 
− Treg subset percentage/number was correlated with increased tumor size and advanced lymphatic invasion (Supplementary Figure 6) .
As for an inverse correlation between intratumoral CD45RA −
− Treg subset and CD8 + T cells (Figure 6d ), next, we evaluated the prognostic value of intratumoral CD45RA −
− Treg/CD8 + T-cell ratio on the survival of GC patients. Comparing patients with high versus low levels of CD45RA −
− Treg/CD8 + T-cell ratio, the 30-month survival rate was significantly lower for those with higher CD45RA −
− Treg/CD8 + T-cell ratio groups (Figure 6e ). Taken together, these findings suggest that increased intratumoral CD45RA − CCR7 − Treg subset is associated with tumor progression and poor survival for GC patients.
Discussion
Many studies focused on tumor-mediated immunosuppression and the subsequent tumor progression over the past decades. 13 Tregs were major component of tumor-infiltrating immune cells with potent immunosuppressive properties in tumor microenvironment.
14 In this study, we have shown that within GC a novel subset of CD45RA −
CCR7
− Tregs play immunosuppressive roles on promoting tumor progression. Although Tregs have already been described in patients with GC tumors, 15 and a higher frequency of Treg cells with effector phenotypes have recently been described in late stage GC, 16 to our knowledge this is the first demonstration of a statistically significant correlation between prevalent CD45RA − CCR7 Tregs are MHC class II restricted CD4 + T cells with the ability to suppress the effector functions of immune cells. 17 Nevertheless, subsets of Tregs that play key roles in tumor immune escape remain largely undefined. In this study, we firstly observed a CD45RA
− memory-phenotyping tumor-infiltrating Tregs in GC. In ovarian tumors, memory Tregs comprise two populations that represent the counterparts of conventional CCR7 + central memory and CCR7 − effector/memory subsets. 18 Therefore, we determine whether such a mechanism existed and was also responsible for the CD45RA − memory Tregs inside our gastric tumors. We further reexamined tumor-infiltrating Tregs according to both CD45RA and CCR7, and confirmed most Tregs showing a CD45RA −
− effector/memory phenotype, which is in accordance with the results on Tregs in squamous cell head/ neck carcinoma regarded as 'effector' phenotype. 19 Collectively, these expression profiles reveal that CD45RA − CCR7 − tumor-infiltrating Treg subset exhibits a phenotype for effector functional features.
Tumor-related inflammation and immunosuppression have been proposed as the hallmarks of cancer. 20 Recently, in human GC, a subset of CD127 low/ − Tregs could exert immunosuppressive properties, although the detailed regulatory mechanisms were not elucidated. 21 In our case, we subsequently identified a novel regulatory mechanism for tumor-derived pro-inflammatory TNF-α: it promotes CD45RA −
− Treg subset induction and downregulates HLA-DR expression by activating intracellular STAT3. STAT3 is critical component of downstream substrates of inflammatory cytokine TNF-α, 22 and is implicated in the regulation of T-cell functions in tumor immunology. 23 Here, we identify STAT3 as a key factor within CD45RA −
− Treg subset induction. It has also been reported that the pro-inflammatory environment may induce the increase of CD45RA −
− Tregs in synovial fluid from patients with rheumatoid arthritis, 24 which resembles our data on CD45RA −
− Treg subset induction by GC tumorderived pro-inflammatory elements. Together with other reported observations that in rheumatoid arthritis CD127 low Tregs accumulated in inflammatory environments and exerted an inhibitory effect on effector T-cell proliferation, 25 it is highly likely that CD45RA −
− Treg subset represents a shared effect of immune suppression in human GC.
Tregs and its subsets are considered as mixed populations, which may mediate immunosuppression through co-stimulation or post-translational modification of the TCR. 26 Most studies have shown that the immunosuppressive activities of Tregs require direct cell-cell contact, which suggests that they function either through cell-surface receptors and/or through the release of soluble mediators. 27 Therefore we have shown that tumor-derived TNF-α effectively inhibit HLA-DR expression on CD45RA 
− Treg cell subsets are increased in GC tumors and correlated with advanced tumor progression and poorer patient survival. Since the clinical outcome for GC patients remains poor and that few prognostic factors currently exist for this disease following surgery, 18 these Treg subsets might be used as clinical markers for GC patients in the future.
In summary, based on our in vitro and in vivo data, we identified in human GC an immunosuppressive pathway, which leads to CD45RA −
− Treg subset induction by tumorderived TNF-α and subsequent CD8 + T cells' suppression and correlates with tumor progression and poor survival. Thus, immune-boosting therapeutic strategies aimed at interfering with this negative pathway may prove beneficial in GC patients. 
Materials and Methods
Patients and tissue samples. Fresh peripheral blood, tumor (homogeneous cellularity, without foci of necrosis, etc.), peritumoral, or autologous non-tumor gastric tissues (peritumoral tissues, 3-4 cm distant from tumor site; non-tumor tissues, at least 5 cm distant from tumor site) were obtained from patients who underwent surgical resection at the Southwest Hospital of Third Military Medical University. None of the patients had received radiotherapy or chemotherapy before surgery. Individuals with autoimmune diseases, infectious diseases, and multiple primary cancers were excluded. Peripheral blood from 45 healthy volunteers was used as controls. The clinical stages of tumors were determined according to the TNM classification system of International Union Against Cancer (Edition 7). Characteristics of the study subjects are summarized in Supplementary Table 1 . The study was approved by the Ethics Committee of the Southwest Hospital of Third Military Medical University, and written informed consent was obtained from all individuals.
Antibodies and other reagents. The antibodies for flow cytometry: for human, anti-CD3-APC-H7 and anti-IFN-γ-PE-Cy7 from BD Pharmingen (San Jose, CA, USA); anti-CD4-FITC, anti-CD25-PE, anti-Foxp3-APC, anti-CD45RA-PE-Cy7, anti-HLA-DR-PerCP-Cy5.5, anti-CCR7-PerCP-Cy5.5, anti-GITR-PE-Cy7, and CD8-PerCP-Cy5.5 from eBioscience (CA, USA); anti-Foxp3-Alexa Fluor 488, anti-CTLA-4-PE-Cy7, anti-CCR4-PE-Cy7, anti-CD44-FITC, anti-CD69-APC-Cy7, and antigranzyme B-APC from Biolegend (San Diego, CA, USA). The antibodies for immunohistochemical staining were as follows: anti-human proliferating cell nuclear antigen (PCNA) from Santa Cruz (Santa Cruz, CA, USA); anti-human CD8 from Dako (Glostrup, Denmark). Horseradish peroxidase (HRP)-conjugated secondary antibodies were from Zhongshan Biotechnology (Beijing, China). The antibodies for neutralizing and blocking were as follows: anti-human TNF-α from R&D Systems; anti-human IL-10 from R&D Systems (Minneapolis, MN, USA). The Abs for western blot: antihuman STAT3 from Cell signaling technology (Beverly, MA, USA); anti-human p-STAT3 (Y705) from Cell signaling technology; HRP-conjugated secondary antibodies were from Zhongshan Biotechnology. Purified anti-CD3 and anti-CD28 Abs were from Biolegend. ELISA kits for human TNF-α and human IL-10 were from eBioscience, ELISA kits for human IFN-γ were from R&D Systems. Collagenase IV, DNase I, DMSO, phorbol 12-myristate 13-acetate (PMA), and ionomycin were from Sigma-Aldrich (St. Louis, MO, USA). Golgistop was from BD Pharmingen. EnVision G2 System/AP Rabbit/Mouse (Permanent Red) was from Dako. The potent STAT3 inhibitor FLLL32 was from MedKoo Biosciences (Morrisville, NC, USA). IκBα inhibitor BAY 11-7082, JNK inhibitor SP600125, and MAPK inhibitor SB203580 were from Calbiochem (Temecula, CA, USA). Carboxyfluorescein succinimidyl ester (CFSE) was from eBioscience. TRIzol reagent was from Invitrogen (Grand Island, NY, USA). Protein Extraction Reagent was from Pierce (Waltham, MA, USA). SuperSignal West Dura Extended Duration Substrate kit was from Thermo (Waltham, MA, USA). FicollPaque Plus was from GE Healthcare (Pittsburg, PA, USA). All recombinant cytokines and chemokines were from PeproTech (Rocky Hill, USA).
Isolation of single cells from GC tissues. In brief, fresh tumor, peritumoral, and non-tumor tissues were washed three times in RPMI 1640 before cut into small pieces. The specimens were then collected in RPMI 1640 containing 1 mg/ml collagenase IV and 10 mg/ml DNase I and mechanically dissociated by using the gentle MACS Dissociator (Miltenyi Biotec, Bergisch Gladbach, GER). Dissociated cell suspensions were further incubated 1 h at 37°C under continuous rotation and filtered through 70-μm cell strainers to obtain cell suspensions.
Tissue culture and preparation of TTCS and NTCS. TTCS or NTCS were prepared by plating autologous tumor or non-tumor gastric tissues in 1 ml RPMI 1640 supplemented with 10% fetal calf serum (FCS) (Gibco, Waltham, MA, USA) for 48 h. Then, the supernatant was centrifuged and collected. + T cells were re-suspended at 2 × 10 5 cells/well in RPMI 1640 containing 10% FCS and seeded in 96-well round bottom plates supplemented with human recombinant (hr) IL-2 (20 IU/ml) and hr TGF-β1 (100 ng/ml), in the presence of anti-CD3 (2 μg/ml) and anti-CD28 antibodies (1 μg/ ml). On day 5, the cells were analyzed for surface CD25 and intracellular Foxp3 expression by flow cytometry. The sorted cells in all experiments were used unless their viability was determined 495% and their purity was determined 497%.
Treg stimulation. Normal Tregs were FACS-sorted (FACSAria II) (BD Biosciences) as CD4 + CD25
+ generated T cells from blood of healthy donors as described above, and were stimulated with 50% TTCS or 50% autologous NTCS for 24 h, or were stimulated with 50% TTCS with a neutralizing antibody against human TNF-α (5, 10 μg/ml), or 50% autologous NTCS with hr TNF-α (5, 10 ng/ml) for 24 h. After stimulation, the cells were collected for flow cytometric analysis and western blot. For the signaling pathway inhibition experiments, these cells were pre-treated with 5 μl FLLL32 (an STAT3 inhibitor), BAY 11-7082 (an IκBα inhibitor), SP600125 (a JNK inhibitor), or SB203580 (a MAPK inhibitor) (the final concentration of all the inhibitors was 20 μM) for 1 h, then were stimulated with 50% TTCS or hr TNF-α (10 ng/ml) for 24 h and collected as above. Since the inhibitors were dissolved in DMSO, parallel cell groups were treated with DMSO (5 μl) or culture media as controls.
Treg subset-CD8 + T-cell co-culture. + T cells at 1 : 1 ratio in the presence or absence of neutralizing antibody against IL-10 (10 μg/ml). In transwell experiments, CFSE-labeled CD8 + T cells were seeded in the lower chamber coated with anti-CD3 (2 μg/ml) and anti-CD28 (1 μg/ ml) antibodies; TTCS-conditioned CD45RA −
CCR7
− Treg subset was then added either in the lower or upper chamber. After 5-day incubation, the supernatants were collected for ELISA, and the cells were analyzed by flow cytometry for CFSE dilution and intracellular cytokine staining. 
− Treg subset was generated from autologous blood and FACSsorted as described above. Then, 1 × 10 6 polyclonal-stimulated (2 μg/ml anti-CD3 and 1 μg/ml anti-CD28) CD8 + T cells were co-cultured with or without TTCS-conditioned CD45RA −
− Treg subset at a 1:1 ratio in the presence or absence of a neutralizing antibody against human IL-10 (10 μg/ml) or a control IgG (10 μg/ml) for 24 h, and were subsequently injected into the peritoneum in 100 μl of buffered saline on day 10 after tumor cell inoculation. Then, mice were injected intraperitoneally with 20 μg of neutralizing antibody against human IL-10 or a control IgG every 2 days until the mice were killed. Tumor size was measured every 2 days by two independent observers using callipers fitted with a vernier scale. Tumor volume was calculated based on three perpendicular measurements. Once the mice were killed, tumors were photographed, and were further paraformaldehyde-fixed for immunohistochemical staining and cut for RNA and protein extraction, and spleens were dissociated into single cells for flow cytometric analysis.
Flow cytometric analysis. Flow cytometric analysis was performed according to standard protocols. For intracellular molecule measurements, the cells were stimulated for 5 h with PMA (50 ng/ml) plus ionomycin (1 μg/ml) in the presence of Golgistop. Intracellular cytokine staining was performed after fixation and permeabilization, using Perm/Wash solution (BD Pharmingen). Cells were analyzed by flow cytometry with FACSCanto II (BD Biosciences). Data were analyzed with Flowjo software (TreeStar) or FACSDiva software (BD Biosciences).
RNA extraction and real-time PCR. RNA of biopsy specimens were extracted with TRIzol reagent. The RNA samples were reversed transcribed to cDNA with PrimeScript RT reagent Kit (TaKaRa, Dalian, China). Real-time PCR was performed on the IQ5 (Bio-Rad, Hercules, CA, USA) with the Real-time PCR Master Mix (Toyobo, Osaka, Japan) according to the manufacturer's specifications. Expression of TNF-α, IL-10, and IFN-γ was measured using the SYBR green method with primers (Supplementary Table 2 ). Human GAPDH served as the ELISA. Human gastric tissues from specimens and mouse tumor tissues were collected, homogenized in 1 ml sterile Protein Extraction Reagent, and centrifuged. Tissue supernatants were collected for ELISA. Concentrations of TNF-α, IL-10 and IFN-γ and in the tissue supernatants and concentrations of IFN-γ (R&D Systems, Minneapolis, MN, USA) in the T-cell culture system supernatants were determined using ELISA kits according to the manufacturer's instructions.
Western blot analysis. Western blot assays were performed on 10-15% SDS-PAGE gels using equivalent amounts of cell lysate proteins of samples. Five percent skimmed milk or 3% BSA was used for blocking the PDF membranes. Human STAT3 and p-STAT3 were detected with anti-STAT3 and anti-p-STAT3 antibodies respectively. This was followed by incubation with HRP-conjugated secondary antibodies. Bound proteins were visualized by using SuperSignal West Dura Extended Duration Substrate kit.
Immunohistochemistry. Paraformaldehyde-fixed and paraffin-embedded samples were cut into 5 μm sections. The sections were incubated with mouse anti-human PCNA or anti-human CD8 antibodies, and then were stained by HRP anti-mouse IgG or using EnVision G2 System/AP Rabbit/Mouse (Permanent Red) followed by diaminobenzidine. All the sections were finally counterstained with haematoxylin and examined using a microscope (Nikon Eclipse 80i; Nikon, Tokyo, Japan).
Statistical analysis. All results are summarized as mean ± S.E.M., and statistical analysis was performed with the SPSS statistical software (version 13.0). Student t-test was generally used to analyze the differences between two groups, but when the variances differed, the Mann-Whitney U test was used. Correlations between parameters were assessed using the Pearson correlation analysis and linear regression analysis as appropriate. Overall patient survival was defined as the interval between date of surgery and date of death or last follow-up, which ever occurred earlier. Cumulative survival time was calculated by the Kaplan-Meier method, and survival was measured in months; the log-rank test was applied to compare between two groups. All data were analyzed using two-tailed tests, and Po0.05 was considered statistically significant.
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